Science & Enterprise subscription

Follow us on Twitter

  • Regenstrief Institute, affiliated with Indiana University, is investing in a new company aiming to improve long-ter…
    about 6 mins ago
  • New post on Science and Enterprise: Institute Invests in Elderly Care Start-Up #Science #Business
    about 9 mins ago
  • Letting academic medical centers make CAR-T drugs would save billions via @statnews
    about 4 hours ago
  • A chain of primary care clinics in grocery stores is adding diagnostics using artificial intelligence to detect an…
    about 21 hours ago
  • New post on Science and Enterprise: Retail Clinics Offer A.I.-Enabled Eye Diagnostics #Science #Business
    about 21 hours ago

Please share Science & Enterprise

DoD Grant Funds Exosome Manufacturing Process

Exosome illustration

Exosome illustration (National Cancer Institute)

26 September 2016. A biotechnology company is receiving a Department of Defense grant to develop a commercial-scale manufacturing process for exosomes, tiny bubbles that deliver drugs to cells in the body. The U.S. Army’s medical research agency awarded Capricor Therapeutics Inc. in Los Angeles some $2.4 million to establish a manufacturing process for exosomes, nanoscale bubbles of natural oils called lipids.

Exosomes are vesicles, tiny — 40 to 150 nanometer — lipid-membrane containers in cells that gather up and secrete cytoplasm, the gel-like material outside the cell nucleus. While originally believed to carry out waste removal and other maintenance tasks, exosomes were shown in recent years to perform useful delivery functions carrying proteins and genetic material to other cells, and drawing increased attention from a range of biological disciplines.

Capricor is a biotechnology enterprise specializing in regenerative medicine, in particular the extraction of cells known as cardiospheres producing stem cells that are introduced back into the coronary arteries of the patient. Capricor says cardiosphere-derived stem cells release growth factors and cytokines, cells that stimulate specific cell responses, signaling the heart to repair itself.

The company is licensing technology from Cedars-Sinai Medical Center in Los Angeles that also extracts exosomes from cardiosphere-derived cells. The company’s first application of exosomes is ocular graft-versus-host disease, a disorder, an immune system disorder that occurs after stem cell or bone marrow transplants. Complications of graft-versus-host disease affecting the eyes include dry eye syndrome and acquisition of eye-related allergies from donors. People with grant-versus-host disease may need to take drugs that suppress the immune system, which raises the risk for infection.

The U.S. military is interested in exosomes as vehicles for reliable, self-contained drug delivery and diagnostics in the field. Among the applications being considered are “nanobots” transported by exosomes with small interfering RNAs, genetic content, or fluorescent reporters. An essay published by the Army earlier this year finds “intriguing” the prospect of manufacturing exosomes loaded with diagnostic or therapeutic payloads.

Capricor first exosome product for ocular graft-versus-host disease is code-named CAP–2003, for which the company expects to file an investigational new drug application in 2017. Linda Marbán, Capricor’s president and CEO says in a company statement, “As a cell-free material, CAP-2003 can be handled and stored in similar fashion to a traditional biopharmaceutical, and may be better suited than cell-based therapeutics for certain applications.”

Marbán adds that “As we advance and expand our exosomes program, this grant from the DoD will support our objective of achieving a commercial manufacturing process for a candidate which we believe has broad treatment potential.”

Read more:

*     *     *

Please share Science & Enterprise ...

Comments are closed.